Literature DB >> 7540602

A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home.

A Gardulf1, G Möller, E Jonsson.   

Abstract

The major aim of this study was to estimate and compare the patient-borne costs of lifelong subcutaneous gamma globulin therapy at the hospital and at home. Thirty patients were included and the data were collected with a questionnaire. The introduction of self-therapy at home reduced the total yearly costs by approximately 50% and the out-of-pocket expenses for the patients by 85%.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540602     DOI: 10.1017/s0266462300006942

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

1.  Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Authors:  U Nicolay; S Haag; F Eichmann; S Herget; D Spruck; A Gardulf
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

2.  Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Authors:  Uwe Nicolay; Peter Kiessling; Melvin Berger; Sudhir Gupta; Leman Yel; Chaim M Roifman; Ann Gardulf; Florian Eichmann; Stefan Haag; Cordula Massion; Hans D Ochs
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

Review 3.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors:  S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

4.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

5.  Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.

Authors:  Roger H Kobayashi; Sudhir Gupta; Isaac Melamed; J Fernando Mandujano; Ai Lan Kobayashi; Bruce Ritchie; Bob Geng; Thomas Prescott Atkinson; Syed Rehman; Eva Turpel-Kantor; Jiří Litzman
Journal:  Front Immunol       Date:  2019-02-04       Impact factor: 7.561

6.  Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

Authors:  Michael C Runken; Joshua M Noone; Christopher M Blanchette; Emily Zacherle; Reuben Howden
Journal:  Am Health Drug Benefits       Date:  2019-10

7.  What Is the Burden of Immunoglobulin Replacement Therapy in Adult Patients With Primary Immunodeficiencies? A Systematic Review.

Authors:  Georgina L Jones; Katharina S Vogt; Duncan Chambers; Mark Clowes; Anna Shrimpton
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.